Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.

van 't Hof AW, Valgimigli M.

Drugs. 2009;69(1):85-100. doi: 10.2165/00003495-200969010-00006. Review.

PMID:
19192938
2.

Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.

Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R; Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators.

JAMA. 2008 Apr 16;299(15):1788-99. doi: 10.1001/jama.299.15.joc80026. Epub 2008 Mar 30.

PMID:
18375998
4.

Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.

Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R; STRATEGY Investigators.

JAMA. 2005 May 4;293(17):2109-17.

PMID:
15870414
6.

Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial.

Valgimigli M, Bolognese L, Anselmi M, Campo G, Rodriguez AE, de Cesare N, Cohen DJ, Sheiban I, Colangelo S, Pasquetto G, Hamon M, Vranckx P, Ferrario M, Prati F, Agostoni P, Malagutti P, Arcozzi C, Parrinello G, Vassanelli C, Ferrari R, Percoco G.

Am Heart J. 2007 Jul;154(1):39-45.

PMID:
17584549
7.
9.

Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Ernst NM, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Zijlstra F, van 't Hof AW.

J Am Coll Cardiol. 2004 Sep 15;44(6):1187-93.

10.
12.

Tirofiban for myocardial infarction.

Juwana YB, Suryapranata H, Ottervanger JP, van 't Hof AW.

Expert Opin Pharmacother. 2010 Apr;11(5):861-6. doi: 10.1517/14656561003690005. Review.

PMID:
20210689
13.

Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab.

Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C.

Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53. Review.

PMID:
21718242
14.

Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.

Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E.

J Am Coll Cardiol. 2010 Aug 3;56(6):463-9. doi: 10.1016/j.jacc.2009.08.093.

15.

Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI.

Xu Q, Yin J, Si LY.

Int J Cardiol. 2013 Jan 20;162(3):210-9. doi: 10.1016/j.ijcard.2012.06.001. Epub 2012 Jul 4.

PMID:
22769575
16.

Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).

Taglieri N, Saia F, Guiducci V, Tondi S, Conrotto F, Marrozzini C, Rocchi G, Biagini E, Reggiani ML, Giacometti P, Piovaccari G, Manari A, Marzocchi A; FATA Trial Investigators.

Am J Cardiol. 2009 Mar 15;103(6):785-90. doi: 10.1016/j.amjcard.2008.11.029. Epub 2009 Jan 21.

PMID:
19268732
17.

Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.

Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH Jr, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.

Circulation. 2002 Sep 17;106(12):1470-6.

18.

Safety and feasibility of a novel dosing regimen of tirofiban administered in patients with acute myocardial infarction with ST elevation before primary coronary angioplasty: a pilot study.

Kochman W, Dobrzycki S, Nowak KS, Chlopicki S, Kralisz P, Prokopczuk P, Bachorzewska-Gajewska H, Gugala K, Niewada M, Mezynski G, Poniatowski B, Korecki J, Musial WJ.

J Thromb Thrombolysis. 2004 Apr;17(2):127-31.

PMID:
15306748
19.

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.

Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial.

N Engl J Med. 2001 Jun 21;344(25):1888-94.

20.

Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.

Gunasekara AP, Walters DL, Aroney CN.

Int J Cardiol. 2006 Apr 28;109(1):16-20. Epub 2005 Jul 12.

PMID:
16014315

Supplemental Content

Support Center